openPR Logo
Press release

Type 2 Diabetes Market Competitive Landscape to 2026| Boehringer Ingelheim, Johnson & Johnson, Novo Nordisk, Glenmark, Poxel, Intarcia, Theracos, Pfizer, Takeda, AstraZeneca, Merck, Sanofi

10-29-2018 08:04 AM CET | IT, New Media & Software

Press release from: Type 2 Diabetes Market

Market Research Report

Market Research Report

Researchmoz added Most up-to-date research on "Type 2 Diabetes: Competitive Landscape to 2026" to its huge collection of research reports.

Type 2 Diabetes: Competitive Landscape to 2026

Summary

Type 2 Diabetes (T2D) is a chronic disease characterized by insulin resistance and pancreatic -cell failure, with an underlying genetic predisposition heavily influenced by diet and lifestyle. Insulin is a hormone that regulates the glucose level in blood. Raised blood sugar (hyperglycemia) is an immediate consequence of diabetes, and over time leads to serious tissue damage, affecting the heart, blood vessels, eyes, kidneys, and nerves. This report provides an assessment of the pipeline, clinical, and commercial landscape of T2D. Overall, GlobalData expects new drug approvals to drive T2D market growth over the next decade (2016-2026).

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1714329

Scope

This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include -
- Pipeline Assessment-regional breakdown, promising late-stage products, early-stage pipeline by molecule type
- Clinical Trials Assessment-trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
- Commercial Assessment-leading marketed products, current and future players
- Competitive Landscape Analysis-key market events (2016-2026).

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Type 2 Diabetes (T2D) market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Type 2 Diabetes (T2D) market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/type-2-diabetes-competitive-landscape-to-2026-report.html/toc

able of Contents

1. Preface 2
1.1 Table of Contents 2
1.2 Abbreviations 3
1.3 Related Reports 4
1.4 Upcoming Related Reports 5

2. Executive Summary 6
2.2 Key Findings 7
2.2 Key Events 8

3. Introduction 9
3.1 Report Scope 10
3.2 Disease Definition and Epidemiology Overview 12

4. Pipeline Assessment 14
4.1 Pipeline Overview 15
4.2 Pipeline Breakdown by Region/Country 17
4.3 Pipeline Breakdown by Molecule Type and Target 18
4.4 Drug Review Designations 19
4.5 Products in Clinical Development 20

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1714329

5. Clinical Trial Assessment 22
5.1 Clinical Trials Overview 23
5.2 Top Sponsors of Clinical Trials in T2D 24
5.3 Trial Breakdown by Region 26
5.4 Therapy Area Perspective 28
5.5 Enrollment Analytics 29

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on Blogger at:https://marketreserch1.blogspot.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Type 2 Diabetes Market Competitive Landscape to 2026| Boehringer Ingelheim, Johnson & Johnson, Novo Nordisk, Glenmark, Poxel, Intarcia, Theracos, Pfizer, Takeda, AstraZeneca, Merck, Sanofi here

News-ID: 1334438 • Views:

More Releases from Type 2 Diabetes Market

Type 2 Diabetes: Causes, Symptoms, Controllable Risk Factors And Treatments
Type 2 Diabetes: Causes, Symptoms, Controllable Risk Factors And Treatments
ResearchMoz present a comprehensive research report namely "Global Type 2 Diabetes Market Research Report 2019" which reveals an extensive analysis of global industry by delivering the detailed information about Forthcoming Trends, Customer’s Expectations, Technological Improvements, Competitive Dynamics and Working Capital in the Market. This is an in-depth study of the market enlightening key forecast to 2025. Type 2 diabetes is a progressive condition in which the body becomes resistant to the
Global Type 2 Diabetes Market Insights, Forecast to 2025 : Novo Nordisk, Sanofi, Merck, Eli Lily, AstraZeneca, Astellas Pharma, Biocon, Daiichi Sankyo, Boehringer Ingelheim
Global Type 2 Diabetes Market Insights, Forecast to 2025 : Novo Nordisk, Sanofi, …
Researchmoz added Most up-to-date research on "Global Type 2 Diabetes Market Insights, Forecast to 2025" to its huge collection of research reports. This report studies the global market size of Type 2 Diabetes in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Type 2 Diabetes in these regions. This research report categorizes the global Type 2 Diabetes market

More Releases for T2D

Explore the Weight Loss & Diabetes Drug Battle: Ozempic vs. Mounjaro vs. Wegovy
Together, Wegovy and Zepbound generated USD 10.8B in recent sales, projected to exceed USD 22.5B by 2034. The weight loss and diabetes drug market is being reshaped by GLP-1-based therapies, led by Novo Nordisk's Ozempic Registered and Wegovy Registered and Eli Lilly's Mounjaro Registered (Zepbound for obesity). Ozempic, already central in type 2 diabetes, has expanded with a new chronic kidney disease (CKD) label, reinforcing its role across the cardio-renal-metabolic spectrum.
Transformational Coach Stephen Leggett Releases Groundbreaking Book "Diabetes Fr …
New Publication Challenges Conventional Wisdom, Offers Alternative Path to Type 2 Diabetes Management Image: https://authoritypresswire.com/wp-content/uploads/2025/08/Messenger_creation_2A9AF9C3-645C-4AE9-8EA2-EE113074E032.jpeg Stephen Leggett [https://thediabetesdestroyer.com/], founder of Reversing Resistance Ltd and creator of The Wellness Codebreaker System, today announced the release of his highly anticipated book "Diabetes Free? My Journey From T2D to Healing and Hope [https://www.amazon.com/dp/B0FJ49KWMZ?ref=cm_sw_r_ffobk_cso_cp_apin_dp_HHG59N7YBNJG147MMYV6&ref_=cm_sw_r_ffobk_cso_cp_apin_dp_HHG59N7YBNJG147MMYV6&social_share=cm_sw_r_ffobk_cso_cp_apin_dp_HHG59N7YBNJG147MMYV6&bestFormat=true&csmig=1]." The publication offers a personal and professional perspective on type 2 diabetes reversal, challenging the conventional approach of lifelong medication management. Drawing from
Type 2 Diabetes Market is Touching New Level – A Comprehensive Study with Key …
Type 2 diabetes (T2D) is a chronic disease that affects bodys blood sugar level. Elevated blood sugar level (hyperglycemia) causes detrimental effects on heart, kidneys, eyes, blood vessels, and nerves. The key players operating in the market include Eli Lilly and Co., Sanofi Aventis A/S, Novo Nordisk, Merck & Co., Inc., Chugai Pharmaceutical Co., Bristol-Myers Squibb, Pfizer Inc., Bayer AG, GlaxoSmithKline Plc., and AstraZeneca Plc. Download Sample PDF Brochure at: https://www.alliedmarketresearch.com/request-toc-and-sample/3964 The
Exclusive Forecast Study: PharmaPoint: Type 2 Diabetes - Global Drug Forecast an …
ResearchMoz presents professional and in-depth study of "PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026". This research assessment offers a clear insight about the influential factors that are expected to transform the global market in the near future. Summary While the global T2D market is crowded with inexpensive generics and marked by a pipeline filled with me-too drugs, GlobalData expects this market to undergo substantial growth between
Type 2 Diabetes Market by Leading Players Eli Lilly and Co., Sanofi Aventis A/S, …
Type 2 diabetes (T2D) is a chronic disease that affects bodys blood sugar level. Elevated blood sugar level (hyperglycemia) causes detrimental effects on heart, kidneys, eyes, blood vessels, and nerves. The key players operating in the market include Eli Lilly and Co., Sanofi Aventis A/S, Novo Nordisk, Merck & Co., Inc., Chugai Pharmaceutical Co., Bristol-Myers Squibb, Pfizer Inc., Bayer AG, GlaxoSmithKline Plc., and AstraZeneca Plc. The major factor that drive the growth
Type 2 Diabetes - Epidemiology Forecast To 2025
Summary Type 2 diabetes (T2D), formerly known as non-insulin dependent diabetes mellitus or adult-onset diabetes mellitus, is a chronic disorder of glucose equilibrium that results from the bodys inability to make use of available insulin along with relative insulin deficiency. T2D constitutes approximately 90% of all diabetes cases around the world; type 1 diabetes (T1D) and gestational diabetes make up the remaining 10% of the cases. Risk factors for T2D are